antisens
oligonucleotid
aso
design
bind
complementari
rna
watsoncrick
hybrid
aso
typic
design
arrest
translat
process
either
induc
cleavag
mechan
involv
endogen
cellular
nucleas
see
front
matter
elsevi
bv
right
reserv
rnase
h
gile
et
al
steric
block
enzym
involv
target
gene
translat
fig
stein
et
al
altern
aso
design
target
viral
genom
region
rna
secondari
structur
involv
transcript
genomicrepl
process
dea
et
al
stone
et
al
asomedi
interfer
virolog
process
inhibit
product
infecti
viru
particl
infect
cell
potenti
reduc
cytopath
effect
illustr
fig
one
unproven
hypothesi
mechan
action
aso
postul
product
defect
interf
particl
follow
aso
treatment
may
facilit
gener
product
immunolog
respons
clear
viru
follow
infect
sinc
discoveri
antisens
molecul
keen
interest
optim
molecular
scaffold
antisens
molecul
improv
pharmaceut
properti
vivo
activ
therapeut
applic
improv
increas
solubl
reduc
toxic
increas
broad
spectrum
activ
engin
phosphorodiamid
morpholino
oligom
pmo
last
year
research
articl
focus
pmobas
antivir
therapeut
agent
overview
effort
develop
antisensebas
therapeut
treatment
viral
bacteri
pathogen
present
sever
recent
review
haasnoot
berkhout
spurger
et
al
stein
warfield
et
al
zamecnik
stephensen
provid
first
report
use
synthet
oligonucleotid
inhibit
pathogen
replic
antisens
mechan
experi
tridecam
oligodeoxyribonucleotid
fig
complementari
rou
sarcoma
viru
rna
introduc
chick
embryo
fibroblast
cell
inhibit
product
viru
investig
reveal
hybrid
oligodeoxyribonucleotid
like
inhibit
replic
block
viral
protein
translat
campbel
et
al
stephenson
zamecnik
wickstrom
find
zamecnik
stephensen
suggest
administr
complementari
antisens
oligonucleotid
aso
might
prove
use
therapeut
approach
achiev
genespecif
knockdown
limit
approach
quickli
realiz
unmodifi
oligodeoxynucleotid
suscept
degrad
endogen
nucleas
cleav
phosphodiest
linkag
present
bodili
fluid
wickstrom
one
first
oligonucleotid
analog
deriv
design
resist
nucleas
degrad
linkag
natur
oligonucleotid
replac
phosphorothio
group
fig
campbel
et
al
find
wheatgerm
reticulocyt
cellfre
translat
assay
show
phosphorothio
oligonucleotid
pto
inhibit
translat
rnase
hdepend
cleavag
mrna
minshul
hunt
matsukura
et
al
first
exploit
antisens
properti
pto
inhibit
replic
hiv
matsukura
et
al
benefit
resist
nucleas
degrad
confer
pto
chemic
modif
diminish
number
offtarget
effect
includ
cleavag
nontarget
sequenc
interact
varieti
protein
activ
b
lymphocyt
activ
complement
henri
et
al
krieg
stein
stein
et
al
summerton
despit
limit
fda
approv
pto
antisens
drug
fomiversen
intravitr
treatment
cytomegaloviru
retin
patient
aid
date
antisens
agent
receiv
approv
therapeut
applic
geari
et
al
perri
balfour
variou
strategi
adopt
attempt
improv
resist
aso
degrad
nucleas
limit
offtarget
effect
enhanc
bind
affin
target
rna
incorpor
omethyl
omethoxyethyl
group
posit
pto
ribos
ring
increas
potenc
nucleas
resist
compar
unmodifi
pto
fig
dean
bennett
turner
et
al
modif
support
rnase
hactiv
led
develop
chimer
strategi
gap
contigu
unmodifi
phosphorothio
nucleotid
analog
incorpor
maintain
rnase
h
activ
retain
favor
properti
modifi
pto
turner
et
al
zheng
lock
nucleic
acid
lna
aso
design
incorpor
methylen
linkag
ribos
fig
comparison
translat
arrest
mechan
mediat
antisens
molecul
typic
translat
process
assembl
ribosom
complex
aug
start
codon
facilit
de
novo
protein
synthesi
templat
rna
complementari
antisens
molecul
arrest
translat
either
steric
block
ribosom
assembl
support
rnase
h
cleavag
activ
aso
mediat
translat
arrest
may
interfer
critic
process
requir
virion
product
assembl
could
promot
format
defect
interf
viral
particl
presenc
alter
protein
defect
particl
may
serv
stimul
product
immunolog
clearanc
mechan
ring
design
support
rnase
h
recruit
fig
kurreck
et
al
veedu
wengel
peptid
nucleic
acid
pna
possess
ribos
ring
reli
instead
peptidebas
structur
molecular
backbon
fig
result
pna
support
rnase
activ
effect
translat
arrest
stericblock
mechan
pna
investig
date
exhibit
poor
cellular
penetr
vivo
pharmacokinet
properti
larsen
et
al
mcmahon
et
al
phosphorodiamid
morpholino
oligom
antisens
molecul
ribos
ring
dna
replac
morpholin
ring
phosphodiest
linkag
replac
phosphorodiamid
linkag
fig
pmo
nonion
charg
statu
contrast
neg
charg
associ
nativ
nucleotid
mani
aso
design
approach
pmo
support
rnase
h
activ
effect
translat
arrest
mrna
process
depend
target
site
steric
block
mechan
untransl
region
utr
transcript
site
near
aug
translat
start
codon
often
target
achiev
translat
arrest
although
suggest
nonion
characterist
pmo
hinder
cellular
uptak
pmo
readili
enter
primari
cell
arora
et
al
iversen
vivo
activ
pmo
antisens
agent
varieti
viral
pathogen
demonstr
discuss
greater
detail
herein
number
neutralcharg
pmo
enter
human
clinic
trial
iversen
iversen
et
al
none
yet
licens
treatment
viral
infect
indic
attempt
improv
vivo
efficaci
pmo
includ
conjug
peptid
design
enhanc
transport
across
cellular
membran
peptid
conjug
pmo
ppmo
fig
includ
posit
charg
amino
acid
residu
arginin
view
particularli
promis
transport
shown
efficaci
multipl
vivo
model
viral
infect
enterlein
et
al
paessler
et
al
stein
swenson
et
al
enhanc
efficaci
ppmo
hypothes
result
enhanc
affin
result
ionic
interact
net
posit
charg
peptid
neg
charg
complementari
rna
enhanc
pharmacokinet
properti
cellular
uptak
iversen
howev
malditof
mass
spectrometri
analys
shown
pmo
portion
ppmo
conjug
stabl
cell
serum
tissu
homogen
peptid
portion
suscept
degrad
amantana
et
al
youngblood
et
al
degrad
impact
effect
ppmo
prevent
effici
escap
conjug
molecul
endosom
lysosom
vesicl
ppmo
efficaci
multipl
vivo
model
viral
infect
ppmo
poorli
toler
vivo
compar
neutralcharg
pmo
mice
dosedepend
reduct
weight
behavior
alter
mild
liver
histopatholog
observ
follow
repeat
administr
lg
dose
pmo
conjug
argininerich
peptid
dea
et
al
rat
administr
mgkg
anticmyc
ppmo
contain
argininerich
peptid
produc
reduct
bodi
weight
elev
serum
blood
urea
nitrogen
creatinin
concentr
chang
observ
follow
dosematch
administr
unconjug
version
pmo
amantana
et
al
variou
attempt
introduc
nonnatur
amino
acid
chemic
chang
conjug
peptid
offset
toxic
improv
cellular
uptak
intracellular
distribut
met
vari
degre
success
abe
et
al
wu
et
al
youngblood
et
al
recognit
positivelycharg
peptid
enhanc
potenc
neutral
charg
pmo
led
design
new
class
posit
charg
pmo
pmoplu
tm
contain
positivelycharg
piperazin
group
along
molecular
backbon
fig
two
recent
report
swenson
et
al
warren
et
al
show
therapeut
well
toler
provid
improv
efficaci
numer
vivo
viral
infect
model
broad
implic
therapeut
develop
virus
highli
pathogen
microb
swenson
et
al
provid
preliminari
find
show
intraperiton
administr
pmoplu
tm
molecul
target
ebola
viru
ebov
mrna
protect
mice
lethal
infect
swenson
et
al
result
expand
upon
report
warren
et
al
show
treatment
confer
postexposur
protect
ebov
separ
marburg
viru
marv
nonhuman
primat
nhp
warren
et
al
achiev
postexposur
efficaci
ebov
nhp
combin
therapeut
contain
pmoplu
tm
molecul
target
ebov
mrna
administ
either
intraven
intraperiton
subcutan
site
warren
et
al
reduc
product
may
facilit
viral
clearanc
host
innat
adapt
immunolog
mechan
limit
interfer
viral
product
type
interferon
induct
signal
process
involv
hartman
et
al
kash
et
al
reid
et
al
studi
show
protect
marv
combin
pmoplu
tm
molecul
target
marv
nucleoprotein
np
deliv
either
intraven
subcutan
intraperiton
subcutan
inhibit
translat
marv
np
may
interfer
releas
viru
infect
cell
bamberg
et
al
marv
genom
synthesi
affect
format
activ
nucleoprotein
complex
dicarlo
et
al
inclus
crossov
neg
control
treatment
nhp
trial
confirm
efficaci
sequencespecif
mediat
nonspecif
mechan
vivo
studi
treatment
well
toler
speci
test
rat
mous
guinea
pig
rhesu
monkey
cynomolg
macaqu
open
investig
new
drug
applic
file
us
food
drug
administr
fda
placebocontrol
doubleblind
phase
clinic
trial
patient
progress
evalu
safeti
mgkg
dose
level
advanc
develop
plan
candid
activ
pursu
reli
licensur
fda
anim
efficaci
rule
regulatori
mechan
design
facilit
develop
new
drug
product
indic
clinic
efficaci
studi
neither
feasibl
ethic
shurtleff
et
al
snoy
current
licens
vaccin
therapeut
product
treatment
ebov
marv
infect
human
report
therapeut
agent
besid
pmoplu
tm
show
substant
postexposur
protect
highli
virul
pathogen
nonhuman
primat
model
geisbert
et
al
geisbert
et
al
find
show
therapeut
protect
marv
ebov
virus
associ
high
case
fatal
rate
certain
outbreak
provid
encourag
class
therapeut
may
efficaci
preval
human
virus
antisens
therapeut
possess
multipl
drug
properti
particularli
favor
use
therapeut
outbreak
scenario
time
viral
outbreak
highli
unpredict
ideal
therapeut
need
stabl
amen
largescal
manufactur
procedur
allow
drug
prepar
advanc
outbreak
pmoplu
tm
agent
amen
midscal
qualitycontrol
manufactur
need
requir
phase
clinic
trial
nonhuman
primat
efficaci
trial
condit
report
herein
molecul
highli
stabl
lyophil
form
follow
purif
solut
highli
solubl
aqueou
solut
isoton
solut
may
administ
clinic
set
initi
investig
nonhuman
primat
demonstr
agent
well
toler
intraven
administr
warren
et
al
suggest
use
emergencyrespons
personnel
like
impact
abil
individu
perform
critic
duti
public
health
medic
crise
pharmacokinet
properti
agent
compris
examin
rat
follow
administr
singl
iv
ip
dose
warren
et
al
plasma
elimin
halflif
follow
iv
administr
mg
kg
rang
h
warren
et
al
halfliv
compar
report
rat
pharmacokinet
analysi
involv
neutralcharg
cmyc
pmo
somewhat
shorter
argininerich
peptid
conjug
version
cmyc
pmo
amantana
et
al
plasma
elimin
halflif
neutralcharg
pmo
sequencedepend
rang
h
amantana
et
al
arora
et
al
iversen
studi
requir
determin
whether
pharmacokinet
behavior
agent
sequencespecif
two
pmoplu
tm
compon
primari
rout
excret
renal
percent
recoveri
total
iv
dose
urin
within
h
administr
agent
exhibit
reduc
renal
clearanc
rel
percent
total
dose
excret
urin
within
h
administ
via
iv
rout
renal
halflif
compon
h
h
follow
ip
administr
agent
gener
rapidli
aborb
time
maxim
plasma
concentr
h
plasma
elimin
halflif
follow
ip
administr
rang
h
plasma
elimin
halflif
may
underestim
tissu
resid
time
may
import
implic
efficaci
neutralcharg
pmo
tissu
resid
time
kidney
liver
report
rang
day
amantana
iversen
iversen
studi
rat
shown
conjug
cmyc
pmo
argininerich
peptid
increas
tissu
uptak
increas
tissu
retent
especi
liver
kidney
spleen
amantana
et
al
tissu
distribut
studi
interspeci
pharmacokinet
comparison
involv
agent
yet
report
investig
ongo
explor
rout
pmoplu
tm
agent
administ
confer
vivo
efficaci
viral
pathogen
result
studi
involv
neutral
charg
pmo
ppmo
suggest
efficaci
achiev
use
administr
via
number
rout
recent
mous
studi
eid
et
al
moerdykschauweck
et
al
shown
ppmo
direct
immedi
earli
gene
icp
administ
topic
eye
genit
tract
epithelium
virus
respect
significantli
reduc
viral
load
tissu
reduc
number
death
infect
ppmo
success
administ
intranas
treatment
respiratori
diseas
influenza
experiment
model
lupfer
et
al
show
fluoresc
label
ppmo
given
intranas
instil
mice
could
detect
lung
tissu
fluoresc
visual
lupfer
et
al
grossli
observ
presenc
fluoresc
pmo
concentr
gradient
decreas
toward
lower
lobe
lung
lupfer
et
al
microscop
ppmo
highest
concentr
around
bronchiol
lupfer
et
al
use
intranas
instil
method
ppmo
deliveri
mice
protect
challeng
influenza
viru
subtyp
demonstr
ppmo
present
situ
concentr
suffici
antivir
activ
lupfer
et
al
mous
model
system
viral
infect
alphavirus
flavivirus
filovirus
use
test
intraperiton
subcutan
intramuscular
intraven
rout
even
combin
thereof
neutralcharg
pmo
ppmo
pmoplu
therapeut
agent
paessler
et
al
warfield
et
al
limit
number
publish
studi
describ
administr
ppmo
neutral
charg
pmo
pmoplu
tm
larger
anim
guinea
pig
cat
nonhuman
primat
treatment
infecti
diseas
cat
treat
caliciviru
infect
mg
dose
neutral
charg
pmo
deliv
subcutan
result
protect
diseas
smith
et
al
intraperiton
treatment
guinea
pig
mg
dose
neutral
charg
pmo
direct
ebov
protein
greatli
enhanc
surviv
lethal
infect
model
warfield
et
al
prophylact
dose
regimen
consist
subcutan
intraperiton
intramuscular
dose
mg
ebovspecif
pmo
protect
rhesu
macaqu
lethal
ebov
infect
warfield
et
al
exist
keen
interest
develop
antivir
therapeut
administ
rapidli
larg
number
individu
minim
involv
medic
profession
accordingli
therapeut
deliv
oral
intramuscular
transderm
rout
particularli
appeal
use
emerg
respons
scenario
use
remot
region
lack
modern
medic
infrastructur
moreov
host
promis
new
technolog
current
develop
drug
administr
includ
genegun
method
taverni
et
al
aerosol
nasal
deliveri
wong
et
al
transderm
dissolv
microneedl
technolog
escobarchavez
et
al
explor
efficaci
antisens
therapeut
deliv
method
may
expand
treatment
option
use
anim
model
investig
experiment
efficaci
pmo
ppmo
shown
activ
human
pathogen
virus
number
famili
dna
rna
virus
publish
efficaci
data
virus
rang
earli
vitro
antivir
activ
studi
vivo
advanc
preclin
develop
studi
anim
model
viral
infect
publish
work
concentr
rna
virus
moerdykschauweck
et
al
neuman
et
al
smith
et
al
smith
et
al
van
den
born
et
al
warren
et
al
virus
belong
taxonom
class
order
gener
similar
genom
structur
gene
function
gene
target
inhibit
effect
aso
one
viru
like
implic
promis
target
relat
virus
neuman
et
al
van
den
born
et
al
fact
virus
possess
conserv
sequenc
region
across
differ
viru
isol
strain
area
sometim
offer
target
pmo
design
gabriel
et
al
holden
et
al
ppmo
inhibit
replic
herp
simplex
cell
cultur
vivo
direct
moerdykschauweck
et
al
gene
express
anoth
larg
dna
viru
iridoviru
character
use
morpholino
knock
viral
gene
express
assess
role
viral
regulatori
gene
protein
sampl
et
al
replic
caliciviru
rna
viru
reduc
cell
cultur
neutral
charg
pmo
concentr
lm
smith
et
al
pmo
use
studi
design
target
felin
caliciviru
fcv
fcv
caus
sever
contagi
febril
respiratori
diseas
cat
kitten
human
calicivirus
categor
categori
b
prioriti
pathogen
niaid
niaid
caus
seriou
infect
given
time
diseas
onset
visibl
sign
subcutan
administr
mgkg
fcv
pmo
result
protect
cat
test
veterinari
field
trial
smith
et
al
prophylact
efficaci
investig
veterinari
clinic
set
virus
order
nidoviral
includ
virus
coronavirida
famili
eg
sever
acut
respiratori
syndrom
coronaviru
sarscov
human
coronavirus
caus
respiratori
gastrointestin
diseas
coronavirus
arterivirus
rna
virus
share
similar
genom
structur
pmo
argininerich
peptideconjug
ppmo
direct
utr
equin
arter
viru
eav
utr
porcin
reproduct
respiratori
syndrom
viru
prrsv
respect
exhibit
antivir
activ
vitro
translat
assay
cell
cultur
han
et
al
patel
et
al
van
den
born
et
al
zhang
et
al
region
arteriviru
genom
inhibit
pmo
also
shown
target
region
inhibit
cov
virus
possess
region
within
utr
genom
term
transcript
regulatori
sequenc
tr
argininerich
peptideconjug
ppmo
direct
sequenc
shown
reduc
sar
cov
yield
vitro
fold
neuman
et
al
prophylact
administr
ppmo
target
utr
genom
region
reduc
liver
viral
load
diminish
hepat
pathophysiolog
mice
infect
murin
hepat
viru
mhv
anoth
betacoronaviru
relat
sar
cov
burrer
et
al
neuman
et
al
howev
viral
challeng
delay
ppmo
treatment
given
therapeut
regimen
protect
anim
burrer
et
al
varieti
studi
human
virus
publish
demonstr
antivir
efficaci
pmo
ppmo
either
cell
cultur
mous
infect
model
subtyp
influenza
virus
repres
common
season
respiratori
pathogen
human
yet
highli
pathogen
virus
emerg
caus
natur
outbreak
collect
vitro
vivo
studi
shown
ppmo
target
translat
start
site
termin
region
np
rna
high
efficaci
sever
subtyp
influenza
gabriel
et
al
ge
et
al
lupfer
et
al
ppmo
test
vitro
strain
protect
mice
lethal
influenza
infect
administ
intranas
viru
challeng
gabriel
et
al
lupfer
et
al
venezuelan
equin
enceph
viru
veev
fastrepl
categori
b
alphaviru
caus
rapid
onset
debilit
ill
human
usual
nonfat
argininerich
peptideconjug
ppmo
direct
utr
aug
region
genom
rna
veev
administ
combin
therapeut
mice
andor
challeng
lethal
dose
virul
veev
strain
paessler
et
al
combin
ppmo
therapi
administ
intranas
intraperiton
lg
lg
given
locat
respect
prechalleng
dose
given
day
h
infect
impart
superior
protect
compar
simpl
daili
administr
combin
therapeut
dose
site
viru
challeng
mice
receiv
ppmo
challeng
protect
mortal
due
veev
infect
mice
surviv
challeng
given
postinfect
dose
regimen
ppmo
within
hour
infect
postexposur
prophylact
paessler
et
al
flavivirus
mani
categor
niaid
categori
b
prioriti
pathogen
reli
conserv
structur
within
utr
viral
genom
form
secondari
stemloop
structur
direct
regul
viral
transcript
translat
review
shurtleff
et
al
west
nile
viru
dengu
viru
type
japanes
enceph
viru
jev
st
loui
enceph
viru
block
argininerich
peptideconjug
ppmo
direct
area
utr
conserv
region
number
dea
et
al
dea
et
al
holden
et
al
kinney
et
al
one
studi
describ
requir
presenc
argininerich
peptid
conjug
pmo
protect
mice
wnv
infect
sinc
subsequ
experiment
trial
use
unconjug
pmo
protect
dea
et
al
increas
surviv
observ
mice
treat
use
prophylact
regimen
postinfect
regimen
argininerich
ppmo
direct
toward
viral
cycliz
sequenc
utr
comparison
treatment
unconjug
version
pmo
flavivirus
argininerich
ppmo
target
viral
cycliz
sequenc
abl
inhibit
jev
infect
differ
cell
type
vitro
prophylact
mous
model
intracerebr
infect
anantpadma
et
al
arenavirus
anoth
viru
famili
caus
signific
human
diseas
limit
treatment
option
peptidelink
pmo
term
ppmo
term
ppmo
terml
design
conserv
sequenc
termini
arenaviru
short
long
rna
segment
evalu
vitro
relat
arenavirus
lymphocyt
choriomening
viru
lcmv
tacarib
viru
pichind
viru
junin
viru
vaccin
strain
candid
neuman
et
al
vitro
ppmo
direct
l
terminu
abl
reduc
viral
np
gp
express
reduc
lcmv
growth
fold
neuman
et
al
ppmo
administ
prophylact
mice
mgkg
prior
infect
lcmv
daili
day
thereaft
signific
reduct
viral
growth
spleen
liver
tissu
observ
upon
sampl
day
neuman
et
al
ppmo
administ
use
prophylact
regimen
evalu
strictli
therapeut
collect
studi
suggest
modifi
pmo
includ
posit
charg
improv
vivo
efficaci
addit
investig
current
progress
evalu
vivo
efficaci
pmoplu
tm
agent
flavivirus
influenza
virus
hemorrhag
fever
virus
clinic
import
viral
pathogen
complementari
design
antisens
molecul
target
rna
confer
high
degre
select
agent
aspect
antisens
therapeut
pose
limit
use
antisens
molecul
viru
variant
possess
mismatch
target
site
two
design
strategi
implement
enhanc
bind
pmoplu
tm
agent
sequenc
variat
known
occur
marv
variant
fig
first
posit
piperazin
moieti
select
posit
site
mismatch
predict
effort
stablil
noncomplementari
base
strengthen
ionic
interact
pmoplu
tm
molecul
target
viral
rna
second
inosin
base
indiscrimin
pair
adenin
uracil
cytosin
incorpor
two
posit
agent
target
marv
mrna
one
posit
agent
target
marv
np
mrna
inosin
residu
posit
produc
complementar
locat
base
known
vari
marv
variant
base
previou
sequenc
analys
efficaci
result
obtain
mous
guineapig
nhp
infect
model
suggest
pmoplu
tm
design
strategi
use
success
accommod
sequenc
predict
mouseadapt
ravn
viru
isol
marvmusok
isol
use
guineapig
nhp
model
marv
infect
warren
et
al
similar
strategi
may
prove
use
design
agent
virus
accommod
limit
mispair
would
predict
among
viru
variant
close
relat
speci
abil
rapidli
develop
produc
therapeut
integr
effici
respond
emerg
situat
involv
pathogen
may
resist
otherwis
insensit
avail
drug
highli
specif
pmo
rapidli
synthes
respons
need
antiebov
morpholinobas
oligom
design
synthes
ship
biocontain
medic
facil
conting
therapeut
within
day
suspect
accident
laboratori
exposur
event
kortepet
et
al
pmoplu
tm
base
therapeut
also
design
prepar
part
formal
rapidrespons
exercis
day
patrick
iversen
person
commun
event
viral
agent
identifi
complet
viral
genom
rna
target
sequenc
avail
time
pmo
request
immedi
synthesi
effort
form
part
biodefens
prepar
also
serv
refin
rapid
respons
requir
scenario
involv
emerg
virus
pathogen
rapid
respons
veterinari
medic
crisi
gener
lethal
outbreak
wnv
humboldt
penguin
occur
milwauke
counti
zoo
pmo
design
synthes
deliv
treatment
within
day
iversen
pmotreat
penguin
surviv
untreat
penguin
die
small
number
anim
involv
event
limit
conclus
drawn
regard
efficaci
pmo
treatment
event
illustr
pmo
quickli
design
deliv
respons
medic
crisi
situat
requir
rel
smallscal
synthesi
pmo
obstacl
associ
largescal
product
technolog
need
overcom
produc
larg
quantiti
therapeut
need
emerg
mass
treatment
outbreak
involv
larg
number
patient
potenti
infect
individu
well
establish
virus
escap
effect
antivir
therapeut
genom
alter
concern
asobas
therapeut
antivir
resist
could
conceiv
occur
propag
minor
variant
contain
nucleotid
polymorph
prevent
effici
bind
antisens
agent
target
nucleotid
sever
report
document
rapid
select
rna
virus
contain
compensatori
mutat
specif
sar
cov
wnv
polioviru
type
footandmouth
diseas
viru
fmdv
enabl
virus
overcom
pmo
antivir
activ
follow
serial
passag
cultur
cell
dea
et
al
neuman
et
al
stone
et
al
vagnozzi
et
al
nucleotid
variat
alter
complementar
target
rna
antivir
antisens
agent
respons
confer
resist
sar
cov
fmdv
howev
wnv
resist
determin
identifi
outsid
ppmo
target
site
viru
serial
passag
presenc
ppmo
target
untransl
conserv
sequenc
csi
dea
et
al
hypothes
mutat
compens
csimedi
disrupt
wnv
genom
cycliz
stein
stein
shi
wnv
isol
brain
infect
mice
treat
csi
ppmo
show
mutat
compar
origin
viru
challeng
stock
dea
et
al
likewis
sequenc
obtain
viru
isol
muscl
ppmotreat
mice
show
mutat
whether
escap
mutant
appear
replic
ebov
marv
infect
nonhuman
primat
treat
antivir
pmoplu
tm
agent
activ
area
research
laboratori
rigor
deepsequencebas
investig
progress
character
occurr
preval
potenti
resist
minor
quasispeci
viru
challeng
stock
virus
isol
infect
nonhuman
primat
pmo
possess
multipl
chemic
properti
favor
use
therapeut
agent
highli
solubl
stabl
storag
biolog
fluid
design
either
fine
degre
antivir
specif
broadspectrum
efficaci
multipl
virus
investig
strive
develop
antisensebas
therapeut
challeng
identifi
aso
chemic
modif
enhanc
vivo
efficaci
candid
therapeut
minim
potenti
toxic
recent
studi
shown
pmoplu
tm
therapeut
agent
confer
high
degre
protect
filovirus
earliergener
morpholino
oligom
ie
neutral
charg
pmo
ppmo
shown
efficaci
varieti
rout
administr
wide
rang
pathogen
stabil
multiplerout
efficaci
pmoplu
tm
agent
make
well
suit
use
varieti
set
includ
region
lack
modern
medic
infrastructur
two
therapeut
agent
enter
phase
clinic
safeti
studi
preclin
efficaci
evalu
progress
addit
therapeut
effort
enhanc
antivir
activ
alreadi
achiev
morpholino
aso
number
viral
pathogen
molecular
backbon
pmoplu
tm
agent
ident
establish
clinic
safeti
profil
one
therapeut
may
serv
expedit
regulatori
review
approv
addit
agent
pmoplu
tm
design
accommod
limit
sequenc
mispair
develop
broadspectrum
antisensebas
therapeut
agent
like
benefit
parallel
approach
target
pathogenspecif
product
hostbas
process
virus
exploit
infect
new
discoveri
made
host
pathway
diverg
virus
reli
entri
replic
exit
infect
cell
new
potenti
target
gene
identifi
assist
effort
develop
broadspectrum
antisensebas
therapeut
opinion
interpret
conclus
recommend
author
necessarili
endors
us
armi
